Published Date : 05 May 2023
The global osteoarthritis therapeutics industry revenue will increase to USD 18.36 billion by 2032 from USD 8.21 billion in 2022 and is poised to grow at a CAGR of 8.38% between 2023 and 2032.
The key elements propelling the development of the examined industry are the rising elderly population, expanding research and development, and financing for osteoarthritis therapies.
Market Growth:
Osteoarthritis (OA) prevalence and burden are rising gradually over the world, posing a significant public health problem in the decades to come. Because there are no particular therapies for OA, it is now understood to be a significant illness with unmet medical needs. A range of possible therapeutic targets implicated in the structural development of OA have been identified as a result of advances in our understanding of the pathophysiology of OA; several of these targets are promising and are currently the subject of clinical research in randomized controlled trials.
Emerging treatments include those that target Wnt signaling, local low-grade inflammation, matrix-degrading proteases, senescent chondrocytes, boosting cartilage repair, or preventing bone remodeling. As the elderly population grows, it is projected that the industry for osteoarthritis treatments would increase. The increased demand for cell-based studies for the disease is anticipated to further stimulate the osteoarthritis treatment industry.
Market Trends:
The industry for treatments for osteoarthritis worldwide includes a thorough examination of the industry in terms of treatments, prognoses, and patient analysis. The report includes a number of data elements, including the death rate, adherence, occurrences, and prevalence. To create a cohort and a strong multivariate statistical model for the aim of estimating the industry across the analysis period, indirect or direct effect analysis of industry growth epidemiology has been examined.
The public's growing knowledge of the condition, the accessibility of improved treatment alternatives, and their willingness to pursue therapy are anticipated to support the industry's expansion for osteoarthritis treatments. The Osteoarthritis (OA) action alliance, for instance, declares May to be Arthritis Awareness Month. Additionally, it mentioned that the most prevalent kind of arthritis is osteoarthritis (OA).
Osteoarthritis Therapeutics Industry Report Scope:
| Report Coverage | Details |
| Market Revenue in 2023 | USD 8.9 Billion |
| Projected Forecast Revenue in 2032 | USD 18.36 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 8.38% |
| Largest Market | Europe |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Regional Snapshot:
Due to the rising incidence of chronic illnesses, the aging population, and changes in people's lifestyles, it is anticipated that the North American industry would expand. As a result, the region's acceptance of diverse treatments and medications is expanding. In comparison to Canada and Mexico, the US will control a sizeable portion of the North American osteoarthritis treatment industry. In 2022, Europe had the most revenue. Europe controlled the industry for osteoarthritis medications. The substantial proportion of this specific industry may be explained by the rising pervasiveness of rheumatoid arthritis, the increasing senior population, as well as increasing obesity rates across various European nations.
However, Asia-Pacific is anticipated to have a CAGR of 8.7% between 2023 and 2032 due to variables such as increasing rates of osteoarthritis, increases in the proportion of women in the population, an increase in healthcare spending, and a lack of physical activity.
Market Dynamics
Drivers: New technological advancement
New OA therapeutics, including platelet-rich plasma (PRP), intra-articular administration methods, stem cell therapies, and antibodies to nerve growth factors, have been made possible by recent technological breakthroughs. (NGF). Although there is still much to learn about these potential treatments, some preliminary results have reportedly been found. PRP is made from plasma, and after centrifugation, a concentrated amount of platelets may be injected back into the area of the body that is afflicted. By applying activated PRP with high concentrations of growth factors, fibrin, and other molecules, it is hypothesized that PRP might induce positive changes in the OA joint by quenching the pro-inflammatory signaling cascade.
Restraints: There may be a negative cardiovascular risk associated with the use of NSAIDs in the treatment of osteoarthritis
NSAIDs, both over-the-counter and on prescription, are often used by patients with osteoarthritis. According to a Bioengineering Document from 2019, more than 60% of Americans with osteoarthritis of the knee accept nonsteroidal anti-inflammatory medicines. Accordingly, in the US, 60.0% of all individuals with knee degenerative joint disease who purchased remedial medications also purchased nonsteroid anti-seditious medications.
Consuming NSAIDs increases the likelihood of developing thoughtful heart disease. Non-selective non-steroidal anti-inflammatory medicines and cox-2-specific non-steroidal anti-inflammatory drugs reduce each other's CVD risk.
Opportunities: personalized therapy for osteoarthritis
A considerable step forward has been made in the analysis, treatment, and assessment of illness severity in patients with knee degenerative joint disease thanks to the conceptualization of modified OA drugs. Easy measurement, an increase in sensitivity and specificity, and counting examination techniques that are friendly and easily readable by surgeons are crucial features that have a quantitative impact on a changed osteoarthritis treatment strategy.
Anatomy Insights:
One of the main causes of old age impairment in individuals all over the world is knee osteoarthritis. Important drivers of the segment's growth include the expanding senior population, increased awareness of knee osteoarthritis, and the rising prevalence of the condition. The increased elderly population, technological improvement in the healthcare industry, and a growth in research and development (R&D) activities related to arthritis. However, due to rising obesity rates, a lack of physical exercise, and an increase in the number of elderly people, the hip osteoarthritis sector is anticipated to have significant growth throughout the projection period.
Drug Type Insights:
Due to increased NSAID drug acceptance, the launch of new products, and an increase in the number of prescriptions, the non-steroidal anti-inflammatory drugs (NSAIDs) segment has accounted for the largest revenue share as of 2022, and this trend is anticipated to continue over the projected timeframe.
Nevertheless, owing to the increasing prevalence of osteoarthritis, improvements in R&D for the development of novel small oil droplet agents, and governmental initiatives to promote research in the healthcare sector, the industry for utilized in an assortment agent is predicted to grow significantly over the course of the forecast period.
Distribution Channel Insights:
In 2022, the industry was led by the hospital pharmacies sector, which also accounted for the greatest revenue share. Pharmacy technicians held the biggest industry share in this category in 2022 because to the large number of patients who received osteoarthritis treatment in clinics and the vast range of osteoarthritis medications that could be obtained from these pharmacists. Nevertheless, it is estimated that the online pharmacy industry would expand significantly over the projected period of time due to advancements in health technology and a rise in demand for remote services.
Recent Development:
September 2022- The Drug Controller General of India (DCGI) granted regulatory permission to Alkem Laboratories for the introduction of StemOne, an over-the-counter cell treatment product, in India. The medicine was introduced by Alkem Laboratories and Stempeutics in order to treat knee osteoarthritis, a degenerative joint condition.
August 2022- A licensing deal was made between Shionogi & Co., Ltd. and Grünenthal GmbH to industry injectable resiniferatoxin, a Grünenthal pipeline product, in Japan. Patients with knee osteoarthritis can use it to relieve their discomfort.
Major Key Players:
Segments Covered in the Report:
By Drugs
By Anatomy
By Purchasing Pattern
By Distribution Channel
By Route of Administration
Buy this Research Report@ https://www.precedenceresearch.com/checkout/2625
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333
